Visterra, Inc.

One Kendall Square, Suite B3301

Cambridge, MA  02139

Tel: 617.498.1070

Brian J. G. Pereira, M.D.
President and Chief Executive Officer


Visterra, Inc.

Flagship Partners:  Ed Kania
Initial Investment: 

Visterra is a biotechnology company that uses its proprietary Hierotope™ Platform to identify unique disease targets and design effective therapeutics. The company’s technology is powered by computational tools and techniques, called Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. The company is currently focused on therapeutics for infectious diseases and its lead antibody product candidate, VIS410, is a broad spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. 

Ed Kania is on the Board of Directors.